Solvay links with HUYA to access Chinese research
This article was originally published in Scrip
Solvay Pharmaceuticals has entered into an agreement with HUYA Bioscience International through which it will gain access to cardiovascular drug candidates coming out of research in China.
You may also be interested in...
Positive clinical results in Parkinson’s pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.